<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431119</url>
  </required_header>
  <id_info>
    <org_study_id>Beissert-BP#1</org_study_id>
    <nct_id>NCT00431119</nct_id>
  </id_info>
  <brief_title>Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid</brief_title>
  <official_title>A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine&#xD;
      or mycophenolate mofetil for the treatment of bullous pemphigoid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter randomized, non-blinded clinical trial compared two parallel groups of&#xD;
      patients with bullous pemphigoid treated with oral methylprednisolone in combination with&#xD;
      either azathioprine or mycophenolate mofetil. Patients were randomly assigned, irrespective&#xD;
      of severity of disease, to receive either 0.5 mg per kg body weight (BW) methylprednisolone&#xD;
      (Urbason®, Aventis Pharma, Bad Soden, Germany) with 2 mg per kg BW azathioprine sodium&#xD;
      (Imurek®, GlaxoSmithKline, Munich, Germany) once daily or 0.5 mg per kg BW methylprednisolone&#xD;
      once daily and 1,000 mg mycophenolate mofetil (CellCept® provided by Hoffmann-La Roche AG,&#xD;
      Grenzach-Wyhlen, Germany), given twice daily (2 g/d). The initial dose was maintained until&#xD;
      blister formation ceased, crusts as well as erosions disappeared, and re-epithelialization of&#xD;
      previous lesions started. The corticosteroid dose was then sequentially reduced by 10 mg&#xD;
      every two weeks until a dose of 20 mg per day was reached followed by a reduction in 5&#xD;
      mg-steps every two weeks until 10 mg per day. Afterwards, corticosteroid reduction was&#xD;
      performed in 2.5 mg-steps every two weeks until zero. After discontinuation of&#xD;
      corticosteroids azathioprine or mycophenolate mofetil doses were maintained at the initial&#xD;
      dosage as monotherapy for an additional 4 weeks. Subsequently, azathioprine was reduced by&#xD;
      0.5 mg per kg BW every four weeks to a dose of 100 mg per day. Thereafter, azathioprine was&#xD;
      tapered in 25 mg-steps every four weeks until discontinuation of treatment. Mycophenolate&#xD;
      mofetil was reduced in 500 mg/d-steps every four weeks to 1,000 mg per day. From then on the&#xD;
      mycophenolate mofetil dosage was decreased in 250 mg-steps every four weeks until&#xD;
      discontinuation of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date>October 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cumulative total methylprednisolone doses and rate of remission.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures were safety profiles and duration of remission.</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine or Mycophenolate mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical lesions suggestive of bullous pemphigoid&#xD;
&#xD;
          -  subepidermal blistering upon histological analysis of skin biopsies&#xD;
&#xD;
          -  linear deposition of IgG and C3 along the dermo-epidermal junction&#xD;
&#xD;
          -  deposition of autoantibodies at the blister roof upon split-skin analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treatment with oral or topical corticosteroids, and other immunosuppressive drugs&#xD;
             during the previous four weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Beissert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology, Univ. of Muenster, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology, Univ. of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. Hospital Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Medical Faculty Mannheim, Univ. of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Municipal Hospital Minden</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Univ. of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Luger TA. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006 Nov;142(11):1447-54.</citation>
    <PMID>17116835</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2007</study_first_posted>
  <last_update_submitted>February 2, 2007</last_update_submitted>
  <last_update_submitted_qc>February 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2007</last_update_posted>
  <keyword>bullous autoimmune disease</keyword>
  <keyword>bullous pemphigoid</keyword>
  <keyword>immunosuppressants</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

